Litigation Details for CIGNA CORPORATION v. CELGENE CORPORATION (D.N.J. 2021)

CIGNA CORPORATION v. CELGENE CORPORATION (D.N.J. 2021)

Docket		Date Filed	2021-05-24
Court	District Court, D. New Jersey	Date Terminated
Cause	15:1 Antitrust Litigation	Assigned To
Jury Demand	Plaintiff	Referred To
Parties	BRISTOL-MYERS SQUIBB COMPANY
Patents	6,045,501; 6,281,230; 6,315,720; 6,555,554; 6,561,976; 6,561,977; 6,755,784; 6,869,399; 7,119,106; 7,141,018; 7,189,740; 7,230,012; 7,465,800; 7,468,363; 7,668,730; 7,855,217; 7,959,566; 7,968,569; 8,204,763; 8,288,415; 8,315,886; 8,404,717; 8,530,498; 8,626,531; 8,648,095; 8,741,929; 9,056,120; 9,101,621; 9,101,622
Attorneys	PETER D. ST. PHILLIP , JR.
Firms	Montgomery McCracken Walker & Rhoads
Link to Docket	External link to docket

Biologic Drugs cited in CIGNA CORPORATION v. CELGENE CORPORATION

Details for CIGNA CORPORATION v. CELGENE CORPORATION (D.N.J. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2021-01-07	1		preventing the Revlimid ‘501 Patent 6,045,501 4-Apr-00 … Patent, ‘886 Patent, ‘717 Patent, ‘498 Patent, ‘531 Patent, ‘095 Patent, ‘120 Patent, ‘621 Patent, …800 Patent, ‘217 Patent, ‘569 Patent, ‘498 Patent, ‘095 Patent, ‘621 Patent, and the ‘622 Patent.100 … ‘800 Patent, ‘217 Patent, ‘569 Patent, ‘498 Patent, ‘095 Patent, ‘621 Patent, and ‘622 Patent.101 … ‘800 Patent, ‘217 Patent, ‘569 Patent, ‘498 Patent, ‘095 Patent, ‘621 Patent, and ‘622 Patent.110 This	External link to document
2022-05-27	40	Amended Complaint	preventing the Revlimid ’501 Patent 6,045,501 4-Apr-00 … Patent, ’886 Patent, ’717 Patent, ’498 Patent, ’531 Patent, ’095 Patent, ’120 Patent, ’621 Patent,…its ’517 Patent, ’720 Patent, ’977 Patent, ’784 Patent, ’740 Patent, ’800 Patent, ’217 Patent, ’569 Patent…200 patent, ’977 Patent, ’784 Patent, ’886 Patent, ’531 Patent, ’800 Patent, ’217 Patent, ’363 Patent…’800 Patent, ’217 Patent, ’569 Patent, ’498 Patent, ’095 Patent, ’621 Patent, and ’622 Patent.182 This	External link to document